A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis

This is a multicenter, randomized, double-blind, placebo-controlled, Phase IIb study to evaluate intra-articular (IA) injections of Allocetra in participants with moderate-to-severe age related symptomatic primary knee osteoarthritis (OA).

开始日期2026-05-01

申办/合作机构

Enlivex Ltd.

[+1]

NCT06748651

/ Recruiting临床1期IIT

Evaluation of Allocetra by Intra-articular Injection for the Treatment of Temporomandibular Joint Osteoarthritis (TMJ-OA)

This study is a single center trial to assess the safety and initial efficacy of intra-articular administration of Allocetra to patients with Temporomandibular Joint Osteoarthritis (TMJ-OA)

开始日期2024-12-15

申办/合作机构

Sheba Medical Center

[+1]

NCT06522035

/ Terminated临床1期

Evaluation of Allocetra by Intra-articular Injection for the Treatment of Psoriatic Arthritis

This is an open label study to evaluate the safety and initial efficacy of intra-articular administration of Allocetra in patients with Psoriatic Arthritis (PsA).

开始日期2024-08-01

申办/合作机构

Enlivex Ltd.

100 项与 Leukocyte cell therapy (Enlivex Therapeutics) 相关的临床结果

登录后查看更多信息

100 项与 Leukocyte cell therapy (Enlivex Therapeutics) 相关的转化医学

登录后查看更多信息

100 项与 Leukocyte cell therapy (Enlivex Therapeutics) 相关的专利（医药）

登录后查看更多信息

项与 Leukocyte cell therapy (Enlivex Therapeutics) 相关的文献（医药）

2024-08-19·MILITARY MEDICINE

Apoptotic Cell–Based Therapy for the Modification of the Inflammatory Response to Hemorrhagic Shock

Article

作者: Lutsker, Maya ; Kolben, Yotam ; Mevorach, Dror ; Wagnert-Avraham, Linn ; Aliev, Emil ; Kenig, Ariel ; Kessler, Asa ; Nachman, Dean

ABSTRACT:

Introduction:

Many trauma patients die from hemorrhagic shock in the military and civilian settings. Although two-thirds of hemorrhagic shock victims die of reasons other than exsanguination, such as the consequent cytokine storm, anti-inflammatory therapies failed to be utilized. Apoptotic cell–based treatments enhance innate ability to exert systemic immunomodulation as demonstrated in several clinical applications and hence might present a novel approach in hemorrhagic shock treatment.

Materials and Methods:

Twenty-two rats underwent a pressure-controlled hemorrhagic shock model and followed up for 24 hours. An infusion of apoptotic cells (Allocetra-OTS, Enlivex Therapeutics Ltd, Nes Ziona, Israel) was administered to the treatment group. Hemodynamics, blood counts, biochemistry findings, and cytokine profile were compared to a saline-resuscitated control group.

Results:

The treatment group’s mean arterial pressure decreased from 94.8 mmHg to 28.2 mmHg, resulting in an 8.13 mg/dL increase in lactate and a 1.9 g/L decrease in hemoglobin, similar to the control group. White blood cells and platelets decreased more profoundly in the treatment group. A similar cytokine profile after 24 hours was markedly attenuated in the treatment group 2 hours after bleeding. Levels of pro-inflammatory cytokines such as interleukin (IL)-1a (28.4 pg/mL vs. 179.1 pg/mL), IL-1b (47.4 pg/mL vs. 103.9 pg/mL), IL-6 (526.2 pg/mL vs. 3492 pg/mL), interferon γ (11.4 pg/mL vs. 427.9 pg/mL), and tumor necrosis factor α (19.0 pg/mL vs. 31.7 pg/mL) were profoundly lower in the treatment group.

Conclusion:

In a pressure-control hemorrhagic shock model in rats, apoptotic cell infusion showed preliminary signs of a uniform attenuated cytokine response. Apoptotic cell–based therapies might serve as a novel immunomodulatory therapy for hemorrhagic shock.

Frontiers in immunology2区 · 医学

Apoptotic Cells for Therapeutic Use in Cytokine Storm Associated With Sepsis– A Phase Ib Clinical Trial

2区 · 医学

ArticleOA

作者: Abutbul, Avraham ; El-Amore, Raja ; Reicher, Barak ; Falah, Batla ; van Heerden, Peter Vernon ; Zlotnick, Eitan ; Nama, Ahmad ; Mevorach, Dror ; Zimro, Sebastian ; Shabat, Yehudit ; Sviri, Sigal

Background:

Sepsis has no proven specific pharmacologic treatment and reported mortality ranges from 30%–45%. The primary aim of this phase IB study was to determine the safety profile of Allocetra™-OTS (early apoptotic cell) infusion in subjects presenting to the emergency room with sepsis. The secondary aims were to measure organ dysfunction, intensive care unit (ICU) and hospital stays, and mortality. Exploratory endpoints included measuring immune modulator agents to elucidate the mechanism of action.

Methods:

Ten patients presenting to the emergency room at the Hadassah Medical Center with sepsis were enrolled in this phase Ib clinical study. Enrolled patients were males and females aged 51–83 years, who had a Sequential Organ Failure Assessment (SOFA) score ≥2 above baseline and were septic due to presumed infection. Allocetra™-OTS was administered as a single dose (day +1) or in two doses of 140×106 cells/kg on (day +1 and +3), following initiation of standard-of-care (SOC) treatment for septic patients. Safety was evaluated by serious adverse events (SAEs) and adverse events (AEs). Organ dysfunction, ICU and hospital stays, and mortality, were compared to historical controls. Immune modulator agents were measured using Luminex® multiplex analysis.

Results:

All 10 patients had mild-to-moderate sepsis with SOFA scores ranging from 2–6 upon entering the study. No SAEs and no related AEs were reported. All 10 study subjects survived, while matched historical controls had a mortality rate of 27%. The study subjects exhibited rapid resolution of organ dysfunction and had significantly shorter ICU stays compared to matched historical controls (p<0.0001). All patients had both elevated pro- and anti-inflammatory cytokines, chemokines, and additional immune modulators that gradually decreased following treatment.

Conclusion:

Administration of apoptotic cells to patients with mild-to-moderate sepsis was safe and had a significant immuno-modulating effect, leading to early resolution of the cytokine storm.

Clinical Trial Registration:

ClinicalTrials.gov Identifier: NCT03925857. (https://clinicaltrials.gov/ct2/show/study/NCT03925857).

Journal of hematology & oncology

Cancer and COVID-19: unravelling the immunological interplay with a review of promising therapies against severe SARS-CoV-2 for cancer patients

Review

作者: Park, Chandler H ; Joshi, Muskan ; Erick, Timothy K ; Menon, Gayathri P ; Cappelli, Jared ; Sharma, Pushpa ; Wilkerson, William B ; Emmanuel, Nancy ; Leyfman, Yan

Abstract:

Cancer patients, due to their immunocompromised status, are at an increased risk for severe SARS-CoV-2 infection. Since severe SARS-CoV-2 infection causes multiple organ damage through IL-6-mediated inflammation while stimulating hypoxia, and malignancy promotes hypoxia-induced cellular metabolic alterations leading to cell death, we propose a mechanistic interplay between both conditions that results in an upregulation of IL-6 secretion resulting in enhanced cytokine production and systemic injury. Hypoxia mediated by both conditions results in cell necrosis, dysregulation of oxidative phosphorylation, and mitochondrial dysfunction. This produces free radicals and cytokines that result in systemic inflammatory injury. Hypoxia also catalyzes the breakdown of COX-1 and 2 resulting in bronchoconstriction and pulmonary edema, which further exacerbates tissue hypoxia. Given this disease model, therapeutic options are currently being studied against severe SARS-COV-2. In this study, we review several promising therapies against severe disease supported by clinical trial evidence—including Allocetra, monoclonal antibodies (Tixagevimab–Cilgavimab), peginterferon lambda, Baricitinib, Remdesivir, Sarilumab, Tocilizumab, Anakinra, Bevacizumab, exosomes, and mesenchymal stem cells. Due to the virus’s rapid adaptive evolution and diverse symptomatic manifestation, the use of combination therapies offers a promising approach to decrease systemic injury. By investing in such targeted interventions, cases of severe SARS-CoV-2 should decrease along with its associated long-term sequelae and thereby allow cancer patients to resume their treatments.

127

项与 Leukocyte cell therapy (Enlivex Therapeutics) 相关的新闻（医药）

2026-06-24

·GlobeNewswire-Health Care

Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume

Ranked second globally in 24-hour spot trading volume, Gate further extends market access and secondary liquidity for Enlivex’s primary digital treasury asset Nes-Ziona, Israel, June 24, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced that its primary treasury asset, the RAIN token, is expected to be listed on the Gate cryptocurrency exchange, effective June 24, 2026 at 10:00 AM UTC. The listing represents a continued expansion of RAIN’s exchange infrastructure, increasing its accessibility, global reach, and token liquidity.According to Gate, it is one of the world’s pioneering cryptocurrency exchanges, established in 2013. Gate is currently serving over 54 million users globally, consistently ranked among the top three digital asset exchanges worldwide by trading volume and liquidity, and holds the second-largest 24-hour spot trading volume globally. Gate supports spot trading, futures trading, margin trading, and wealth management products for over 4,600 cryptocurrencies. “Gate is one of the most established and widely accessed cryptocurrency exchanges in the world,” stated Oren Hershkovitz, CEO of Enlivex. “Exchange listings on platforms of this caliber expand the secondary market infrastructure around our primary treasury asset. We view each such listing as a positive step in building the long-term accessibility and market depth of our RAIN holdings.” Enlivex’s digital asset treasury strategy is focused on the acquisition of RAIN tokens. The Company previously announced that, as of June 21, 2026, it held 79,568,550,005 RAIN tokens with a total value of approximately $1.14 billion1, representing a treasury NAV per Share of $4.67. The updated unaudited mark-to-market treasury metrics are publicly available on the Company’s website at https://enlivex.com/dashboard/. Detailed information about the RAIN token’s listing on various exchanges, daily trading volume and other parameters can be found on https://coinmarketcap.com/currencies/rain/. RAIN serves as the governance and utility token of a fully decentralized predictions and options protocol built on the Arbitrum network. The protocol enables users globally to create, trade, and resolve markets tied to real-world events through a transparent and automated on-chain framework. About EnlivexEnlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem. Forward-looking statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “target,” “has the potential to,” “goal,” and other words of similar meaning, including statements relating to the anticipated benefits of the Company’s digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company’s ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company’s plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Company’s digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company’s operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company’s ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law. Enlivex contactShachar ShlosbergerCFOEnlivex Ltd.shachar@enlivex.com 1 Valuation calculated using the closing price of the token as quoted on https://coinmarketcap.com/currencies/rain/

免疫疗法

2026-06-22

·GlobeNewswire-Health Care

Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion

As of June 18, 2026, Enlivex held 79,568,550,005 RAIN tokens with a total value of approximately $1.14 billion1. Nes-Ziona, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today provided an update on its RAIN token holdings. As of June 20, 2026, the Company held 79,568,550,005 RAIN tokens with a total value of approximately $1.14 billion1. The Company's treasury metrics, as reflected on its public market data dashboard, indicate a Treasury NAV per Share of $4.671 as of June 20, 2026, based on current RAIN token holdings relative to total number of the Company’s ordinary shares outstanding. The updated unaudited mark-to-market treasury metrics are publicly available on the Company's website at https://enlivex.com/dashboard/. Detailed information about the token’s listing on various exchanges, daily trading volume and other parameters can be found on https://coinmarketcap.com/currencies/rain/. About EnlivexEnlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem. Forward-looking statementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would," "could," "intends," "estimates," "suggests," "target," "has the potential to," "goal," and other words of similar meaning, including statements relating to the anticipated benefits of the Company's digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company's ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company's plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Company's digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company's operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company's ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law. Enlivex contactShachar ShlosbergerCFOEnlivex Ltd.shachar@enlivex.com 1 Valuation calculated using the closing price of the token as quoted on https://coinmarketcap.com/currencies/rain/

免疫疗法财报

2026-06-15

·GlobeNewswire-Health Care

Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis

Nes-Ziona, Israel, June 15, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced the issuance of an Australian patent, numbered 2020340629, titled, “THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITIS”. The patent will provide Enlivex with added intellectual property protection in Australia through at least 2040 with claims covering methods of using Allocetra™ to treat subjects with osteoarthritis. With this issuance, the Company has secured patent protection for Allocetra™ in osteoarthritis in an additional major jurisdiction, further strengthening its global intellectual property position as the Phase 2b clinical program for Allocetra™ advances. Enlivex recently reported the dosing of the first patient at a U.S. clinical site in the Phase 2b clinical trial of Allocetra™ for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis (OA). The Phase 2b follows Enlivex’s previous announcement regarding positive three-month and six-month topline data from the Phase 2b stage of ENX-CL-05-001, a multi-center, two-stage Phase I/II double-blind, randomized, placebo-controlled clinical trial that evaluated Allocetra™ in patients with moderate-to-severe knee OA. About Enlivex (Nasdaq: ENLV) Enlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem. About Knee Osteoarthritis Knee osteoarthritis (KOA) is one of the most prevalent and disabling diseases worldwide, affecting more than 32 million Americans today and projected to impact 78 million Americans by 2040. There are currently no approved disease modifying therapies; treatment is largely limited to pain relief, intra-articular steroids, or surgery, and the burden increases sharply with age. By age 60, KOA affects roughly 30% of the population, and about half of knee OA patients are 60 years and older. This demographic is expanding with global aging trends, underscoring the need for new, durable therapies. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would," "could," "intends," "estimates," "suggests," "target," "has the potential to," "goal," and other words of similar meaning, including statements relating to the anticipated benefits of the Company's digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company's ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company's plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Company's digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company's operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company's ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law. ENLIVEX CONTACT Shachar Shlosberger, CFO Enlivex Ltd. shachar@enlivex.com

临床2期免疫疗法临床结果

100 项与 Leukocyte cell therapy (Enlivex Therapeutics) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
膝关节炎	临床2期	以色列	Enlivex Ltd.	2024-01-26
晚期恶性实体瘤	临床2期	以色列	Enlivex Ltd.	2022-11-15
晚期恶性实体瘤	临床2期	西班牙	Enlivex Ltd.	2022-11-15
转移性肿瘤	临床2期	以色列	Enlivex Ltd.	2022-06-29
腹膜继发性恶性肿瘤	临床2期	以色列	Enlivex Ltd.	2022-06-29
急性呼吸窘迫综合征	临床2期	以色列	Enlivex Ltd.	2021-09-01
胆管炎	临床2期	比利时	Enlivex Ltd.	2020-11-30
胆管炎	临床2期	法国	Enlivex Ltd.	2020-11-30
胆管炎	临床2期	以色列	Enlivex Ltd.	2020-11-30
胆管炎	临床2期	荷兰	Enlivex Ltd.	2020-11-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06233474 (ENX-CL-05-001, EULAR2026)	临床2期	膝关节炎	134	Allocetra	構簾鏇簾選醖廠醖獵顧(鏇製衊獵觸廠構鹹醖簾) = 夢鹽觸築鏇鏇餘範廠窪觸繭衊醖繭獵壓衊淵鏇 (簾鏇窪願網鏇製網廠鹹 ) 更多	积极	2026-06-11
				Placebo	壓廠簾積艱築製鹽膚積(衊憲構夢顧鏇壓簾餘窪) = 廠壓築艱醖遞製醖積遞製築鹽醖選壓積範願鬱 (願襯壓簾積製餘鹽網衊 )
NCT06233474 (ENX-CL-05-001 \| ENXCL05001, GlobeNewswire) 人工标引	临床2期	膝关节炎	-	Allocetra	鹹鹽網選鹽蓋衊製壓餘(糧艱築鹹鹽蓋壓簾獵蓋) = 繭膚構膚衊壓壓鬱鏇構網壓遞選齋齋窪網繭簾 (構觸窪構繭淵製衊構蓋 ) 更多	积极	2025-11-24
				Placebo	鹹鹽網選鹽蓋衊製壓餘(糧艱築鹹鹽蓋壓簾獵蓋) = 鹹選糧選齋艱積製憲鹹網壓遞選齋齋窪網繭簾 (構觸窪構繭淵製衊構蓋 ) 更多
NCT06233474 (ENXCL05001, GlobeNewswire)	临床1/2期	骨关节炎 \| 膝关节炎	130	AllocetraOTS	齋夢糧鑰衊範艱膚簾衊(鑰鬱窪壓鬱願廠襯壓構): Difference (%) = 26 更多	积极	2025-08-18
				placebo
EULAR2025	临床1/2期	膝关节炎	15	AllocetraTM	窪夢壓膚糧夢鬱窪鏇網(積構鏇簾廠築製齋範築) = 簾襯觸繭廠構餘艱顧憲艱齋積簾襯鏇醖鏇鏇衊 (顧衊蓋構觸醖憲遞衊襯, 35.1 ~ 69.7) 更多	积极	2025-06-11
NCT06233474 (GlobeNewswire) 人工标引	临床1/2期	膝关节炎	12	Allocetra	觸構艱廠網淵選淵蓋獵(選鏇艱衊鹽鏇範廠憲積) = 鹹壓觸觸鹹膚鏇廠醖選膚淵積醖膚製糧淵顧廠 (製構顧網積襯襯簾鹹構 ) 更多	积极	2024-12-03
NCT06233474 (Biospace) 人工标引	临床1/2期	膝关节炎	9	Allocetra	蓋夢顧鏇範窪醖獵醖憲(糧醖夢築簾鏇範積遞壓) = 構構積膚積襯觸構繭鬱積繭鹽願憲廠襯鹹夢淵 (範鑰襯憲鹹獵獵築齋襯 ) 更多	积极	2024-06-17
NCT04612413 (GlobeNewswire) 人工标引	临床2期	脓毒症	-	Allocetra	範顧齋壓齋鹹鏇夢糧製(憲鬱願願積鏇鬱廠淵鬱) = 鬱廠積鹹鹽顧餘膚齋鏇艱廠遞獵鏇鬱窪簾範繭 (餘顧鏇糧壓廠憲艱選壓 ) 更多	积极	2024-04-11
NCT03925857 (P-SOFA-1, Pubmed \| Front Immunol) 人工标引	临床1期	脓毒症	10	Allocetra™-OTS	窪鹹衊構艱鏇醖範繭蓋(廠醖窪憲獵夢顧餘鑰顧) = No SAEs were reported. 餘築鬱簾顧鹽製獵蓋醖 (齋觸衊齋壓淵積淵築糧 ) 更多	积极	2021-09-30
				historical controls
NCT04590053 (GlobeNewswire) 人工标引	临床2期	新型冠状病毒感染	16	Allocetra	壓窪醖廠繭繭鹹蓋餘壓(餘壓鏇襯顧艱壓構繭遞) = 憲襯願憲窪艱衊襯壓願築蓋簾製積觸觸衊範糧 (蓋鏇憲蓋膚網蓋遞餘構 ) 更多	积极	2021-02-03
NCT03925857 (P-SOFA-1, GlobeNewswire) 人工标引	临床1期	脓毒症	47	Allocetra	餘範顧蓋膚艱顧窪夢範(糧窪願鏇壓窪構鏇齋願) = 願餘壓艱簾觸鏇遞餘齋鬱網網壓鹹膚餘鏇蓋艱 (遞齋齋願鹹鬱獵網夢繭 ) 更多	积极	2020-03-18
				Standard of Care	襯壓網壓襯鏇簾顧膚鬱(繭艱鏇鏇淵齋窪艱鬱膚) = 淵憲鹽窪構糧繭鹹餘餘廠憲築艱廠網構淵鹽蓋 (醖襯製廠網艱醖構膚顧 ) 更多